UC BRAID

- Drug and Device Discovery and Development (D4)
- UC Center for Accelerated Innovation

June Lee, MD (UCSF)
D4 Chair
UC-CAI site head, therapeutics review chair

October 16, 2015
D4 workgroup

Objective: to leverage the combined strengths and resources of UC schools to accelerate the translation of academic basic research discoveries into valuable therapies

Areas of focus
- Academic-Private Partnerships
- Training and Mentorship
- Translational Resource Sharing
- Collaborations and Grant Opportunities

High Priority Initiatives
(from April 2015 summit)
1. Multi-campus partnerships with industry
2. UC Drug Discovery Alliance
Multi-campus partnerships with industry

• **Goals**
  – Increase competitiveness of the UCs for significant industry partnerships
  – Leverage industry resources (funding, know-how, capabilities) to accelerate translation of promising technologies

• **Status**
  – Conducted a survey of major pharma, device and diagnostics companies to confirm interest and identify perceived challenges
  – Engaged key stakeholders on each UC BRAID campus
  – Created a framework and management process for negotiations across BRAID campuses

• **Next steps**
  – Identify and engage an industry partner
UC Drug Discovery Alliance

Ensuring that promising therapeutic discoveries across UC achieve clinical impact

• Goals
  – Identify most promising research programs with high therapeutic potential across UC
  – Support those programs through critical target-to-candidate activities to increase value (IP, funding and partnering opportunities)
  – Leverage knowledge, capabilities, infrastructure across UC
  – Complement with knowledge and resources of industry partners

• Status
  – Engaged stakeholders on each UC BRAID campus
  – Developed potential DDA models

• Next steps
  – Identify resources for dedicated effort
UC CORE

Web-based compendium of translational core facilities across UC campuses

- **Goal**
  - To facilitate access and increase utilization of translational facilities across UC

- **Key features:** task-centric layout, emphasis on unique facilities, up-to-date, transparent

- **Status:** development in progress, launch expected Q1 2016
CAI Overview

• Five UC medical campuses
  – Davis, Irvine, LA, San Diego, San Francisco
• One of three centers nationally
  – Harvard, Cleveland Clinic
• NHLBI - $12 million, NIDA - $3 million
• Overarching purpose:
  – Translate basic science advances and discoveries into commercially viable products for:
    • heart, lung and blood disease patients
    • treatment of substance use disorders
Goals

• Engage University of California research innovators in entrepreneurship through a comprehensive education, training and mentorship program.

• **Solicit and select technologies** with high commercial potential that align with NHLBI or NIDA’s mission and address unmet medical needs or significant scientific opportunity.

• **Incubate** our most promising technologies in accordance with industry requirements to facilitate their translation to commercial products that improve patient care and enhance health.

• Create a high-performing, sustainable infrastructure that will serve as a model to academic research centers.
### NHLBI RFA Response (3 cycles)

<table>
<thead>
<tr>
<th></th>
<th>Pre-Application</th>
<th>Full Application</th>
<th>Funded</th>
</tr>
</thead>
<tbody>
<tr>
<td>Device</td>
<td>52</td>
<td>26</td>
<td>8</td>
</tr>
<tr>
<td>Diagnostic</td>
<td>41</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Therapeutic</td>
<td>55</td>
<td>28</td>
<td>4</td>
</tr>
<tr>
<td>Tool</td>
<td>8</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>156</strong></td>
<td><strong>63</strong></td>
<td><strong>16</strong></td>
</tr>
</tbody>
</table>

### NIDA RFA Response (1 cycle)

<table>
<thead>
<tr>
<th></th>
<th>Pre-Application</th>
<th>Full Application</th>
<th>Funded</th>
</tr>
</thead>
<tbody>
<tr>
<td>Device</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diagnostic</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Therapeutic</td>
<td>9</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>Tool</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>14</strong></td>
<td><strong>7</strong></td>
<td><strong>2</strong></td>
</tr>
</tbody>
</table>
Skills Development

Webinars

**Archived**
- Small Molecule Drug Development
- Antibody Therapeutics
- Technology Assessment
- Mistakes Academics make with IP
- SBIR Applications

**Upcoming**
- Regulatory Issues
- Reimbursement Process
- Estimating Market Size
- IP for Therapeutics and Devices
- US vs European Patent Laws

**530 unique registrants (74% live participation) across UC CAI, Boston and Cleveland NCAIs, and NHLBI**

I-CORPs
- 24 teams

Consultations
- Successful re-submissions in later cycles
- Venture capital funding, SBIR funding
Upcoming CAI Activities

• Device Retreat at UC Irvine

• CAI Advisory Boards
  – External Advisory Board
  – Business Review Panel
  – Technology Transfer Board

• Cross-campus business development
  – Best in practice product profile, process to license, regulatory strategies, reimbursement
  – Define optimal exit

• RFA
  – NHLBI Cycle 4
  – NIDA Cycle 2
Acknowledgements

**D4 Leadership**
- June Lee (UCSF)
- Robert Damoiseaux (UCLA)
- Michael Gilson (UCSD)
- Vicki Feher (UCSD)
- Michael Rogawski (UCD)
- Weian Zhao (UCI)
- Cathy Tralau-Stewart (UCSF)
- Irina Gitlin (UCSF)

**CAI Leadership**
- Michael Palazzolo (UCLA) - Director
- Tom Ganz (UCLA) – Associate Director
- Elliot Botvinick (UCI)
- Bill Boyle (UCLA)
- Kirk Knowlton (UCSD)
- June Lee (UCSF)
- Laura Marcu (UCD)
- Bob Ross (UCSD)
- Vish Krishnan (UCSD) – Skills Development